PROVERA

This brand name is authorized in Australia, Brazil, Canada, Ecuador, Estonia, Finland, Hong Kong, Croatia, Ireland, Israel, Japan, Malta, Mexico, Netherlands, New Zealand, Poland, Singapore, United Kingdom, United States, South Africa

Active ingredients

The drug PROVERA contains one active pharmaceutical ingredient (API):

1 Medroxyprogesterone
UNII C2QI4IOI2G - MEDROXYPROGESTERONE ACETATE

Medroxyprogesterone acetate exerts anti-oestrogenic, anti-androgenic and antigonadotrophic effects.

Read about Medroxyprogesterone

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
PROVERA Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
G03AC06 Medroxyprogesterone G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AC Progestogens
Discover more medicines within G03AC06
G03DA02 Medroxyprogesterone G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03D Progestogens → G03DA Pregnen (4) derivatives
Discover more medicines within G03DA02
L02AB02 Medroxyprogesterone L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AB Progestogens
Discover more medicines within L02AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 2316X, 2321E, 2323G, 2722G, 2725K, 2727M, 2728N
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 522717120067907
Country: CA Health Products and Food Branch Identifier(s): 00030937, 00708917, 00729973
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 28850-05-09, 28854-05-09
Country: EE Ravimiamet Identifier(s): 1009022, 1009044, 1063594, 1083541, 1764019
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 500066
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 143567, 143574, 162293, 176262, 21979, 21984, 22017, 22019, 22022, 22134, 22135, 28266, 28289, 374122, 374129, 374130, 381931, 38689
Country: HK Department of Health Drug Office Identifier(s): 00445, 00488
Country: IE Health Products Regulatory Authority Identifier(s): 43628, 43637, 43645
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 128
Country: JP 医薬品医療機器総合機構 Identifier(s): 2478002F1070
Country: MT Medicines Authority Identifier(s): AA565/00102, AA565/00103, AA565/00104
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 59797
Country: NL Z-Index G-Standaard, PRK Identifier(s): 159, 17442, 20389, 21822
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 293, 294, 296, 297, 299
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100056339, 100056345
Country: SG Health Sciences Authority Identifier(s): 03841P, 10513P
Country: US FDA, National Drug Code Identifier(s): 0009-0050, 0009-0051, 0009-0065, 0009-0286, 0009-0287
Country: ZA Health Products Regulatory Authority Identifier(s): S/21.8.2/1, W/21.8.2/462, Z/21.8.2/363

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.